Please login to the form below

Not currently logged in
Email:
Password:

insulin peglispro

This page shows the latest insulin peglispro news and features for those working in and with pharma, biotech and healthcare.

Lilly's Lantus 'follow-on' approved in the US

Lilly's Lantus 'follow-on' approved in the US

The settlement did not cover insulin glargine sold in vials or combination products. ... Approval is a boost to Lilly, which decided earlier this month to abandon development of another Lantus rival - insulin peglispro - after concluding data on a

Latest news

  • Lilly says insulin peglispro too risky to pursue Lilly says insulin peglispro too risky to pursue

    Lilly says insulin peglispro too risky to pursue. Discontinues development of medicine once tipped as a diabetes blockbuster. ... Eli Lilly has decided to discontinue development of insulin peglispro, a drug once considered a potential blockbuster for

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    Novo Nordisk finally bags insulin degludec approval in US. Aims to get Tresiba and Ryzodeg back on course . ... However, there was some good news for Novo Nordisk when it emerged Eli Lilly had delayed filings for its long-acting insulin peglispro

  • Rivals look to put pressure on Sanofi's Lantus Rivals look to put pressure on Sanofi's Lantus

    The American Diabetes Association's (ADA) Scientific Sessions meeting in Boston this weekend saw several of Sanofi's rivals claim clinical benefits over its blockbuster Lantus (insulin glargine). ... The company also released the results of five phase

  • Sanofi wins European approval for Lantus follow-up Toujeo Sanofi wins European approval for Lantus follow-up Toujeo

    Sanofi wins European approval for Lantus follow-up Toujeo. Long-acting insulin is a key part of the company's growth plans. ... However, the company will have slightly longer to establish Toujeo than it originally expected after regulatory filings for

  • FDA starts review of Novo's refiled diabetes pair FDA starts review of Novo's refiled diabetes pair

    The US FDA has started a fresh review of Novo Nordisk's long-acting insulin therapies Tresiba and Ryzodeg, which it turned down two years ago. ... Until recently, additional competition was also looming in the form of Lilly's long-acting insulin peglispro

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics